PSA Prodrug-Based Multimodality Agents for Imaging Metastatic Prostate Cancer
Abstract
The purpose of this work is to prepare and test a series of PSA binding prodrugs which contain both a fluorescent and radioactive group which can bind to enzymaticly active PSA in the vicinity of the tumor where the polar peptide portion is cleaved producing a lipophilic cleavage product which intercalates in the cell membrane of the tumor and nearly cells. In this period we made progress in the synthesis of iodinated and radioiodinated fluorescent PSA prodrugs and PSA cleavage products. In particular we were able to introduce the acid labile tributyl tin moiety needed to incorporate the radioiodine into the molecule towards the end of the synthetic route.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2010
- Accession Number
- ADA525527
Entities
People
- Ronnie C. Mease
Organizations
- Johns Hopkins Hospital